Published in J Cardiovasc Transl Res on May 13, 2014
The chromogranin-secretogranin family. N Engl J Med (2003) 4.28
Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol (1998) 3.58
QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation (1991) 3.25
Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation (1997) 2.53
Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest (2005) 2.19
Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J (2002) 1.98
Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens (2002) 1.65
Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res (1974) 1.64
Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens (2010) 1.54
Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides (1998) 1.24
P-R interval in relation to heart rate during exercise and the influence of posture and autonomic tone. J Electrocardiol (1977) 1.18
Chromogranin A in human hypertension. Influence of heredity. Hypertension (1995) 1.18
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens (2001) 1.17
Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation (2008) 1.12
Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J Biol Chem (2011) 1.09
Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology (2009) 1.07
Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press (1999) 1.07
Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med (2003) 1.03
Genetic influence on electrocardiogram time intervals and heart rate in aging mice. Am J Physiol Heart Circ Physiol (2009) 1.02
Subclinical cardiomyopathy in Becker muscular dystrophy. Br Heart J (1992) 1.02
Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol (2010) 0.97
Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation. J Electrocardiol (2004) 0.97
Knock-out of the potassium channel TASK-1 leads to a prolonged QT interval and a disturbed QRS complex. Cell Physiol Biochem (2011) 0.93
Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept (1995) 0.93
The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens (2006) 0.92
Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem (2008) 0.90
A study of the human heart as a multiple dipole electrical source. II. Diagnosis and quantitation of left ventricular hypertrophy. Circulation (1969) 0.88
Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology (2010) 0.87
Real-time 12-lead high-frequency QRS electrocardiography for enhanced detection of myocardial ischemia and coronary artery disease. Mayo Clin Proc (2004) 0.87
The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion. Biochemistry (2008) 0.86
Full-length human chromogranin-A cardioactivity: myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts. Endocrinology (2013) 0.86
The cardiomyopathy of Duchenne/Becker consultands. Int J Cardiol (1992) 0.86
Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout. Physiol Genomics (2009) 0.84
The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364). Properties and function. Adv Exp Med Biol (2000) 0.84
Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling. Postgrad Med J (2012) 0.83
Reprint of: Catestatin: a multifunctional peptide from chromogranin A. Regul Pept (2010) 0.82
Chromogranin A induces the biogenesis of granules with calcium- and actin-dependent dynamics and exocytosis in constitutively secreting cells. Endocrinology (2012) 0.81
[Ventricular repolarization and Holter monitoring. Effect of sympathetic blockage on the QT/RR ratio]. Arch Mal Coeur Vaiss (2000) 0.81
QT interval prolongation and increased plasma catecholamine levels in patients with mitral valve prolapse. Am Heart J (1983) 0.80
The chromogranins. Historical perspectives. Adv Exp Med Biol (2000) 0.79
Assessment of atrioventricular nodal physiology in the mouse. J Interv Card Electrophysiol (1999) 0.79
Myocardial infarction diminishes both low and high frequency QRS potentials: power spectrum analysis of lead II. J Electrocardiol (1981) 0.78
ECG alterations with progressive left ventricular hypertrophy in spontaneous hypertension. Clin Exp Hypertens (1978) 0.77